SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab

Detalles Bibliográficos
Autores principales: Stiasny, Karin, Weseslindtner, Lukas, Heinzel, Andreas, Camp, Jeremy V., Oberbauer, Rainer, Reindl-Schwaighofer, Roman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Health Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790897/
https://www.ncbi.nlm.nih.gov/pubmed/36578452
http://dx.doi.org/10.3389/ti.2022.10906
_version_ 1784859278732951552
author Stiasny, Karin
Weseslindtner, Lukas
Heinzel, Andreas
Camp, Jeremy V.
Oberbauer, Rainer
Reindl-Schwaighofer, Roman
author_facet Stiasny, Karin
Weseslindtner, Lukas
Heinzel, Andreas
Camp, Jeremy V.
Oberbauer, Rainer
Reindl-Schwaighofer, Roman
author_sort Stiasny, Karin
collection PubMed
description
format Online
Article
Text
id pubmed-9790897
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97908972022-12-27 SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab Stiasny, Karin Weseslindtner, Lukas Heinzel, Andreas Camp, Jeremy V. Oberbauer, Rainer Reindl-Schwaighofer, Roman Transpl Int Health Archive Frontiers Media S.A. 2022-12-12 /pmc/articles/PMC9790897/ /pubmed/36578452 http://dx.doi.org/10.3389/ti.2022.10906 Text en Copyright © 2022 Stiasny, Weseslindtner, Heinzel, Camp, Oberbauer and Reindl-Schwaighofer. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Health Archive
Stiasny, Karin
Weseslindtner, Lukas
Heinzel, Andreas
Camp, Jeremy V.
Oberbauer, Rainer
Reindl-Schwaighofer, Roman
SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab
title SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab
title_full SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab
title_fullStr SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab
title_full_unstemmed SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab
title_short SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab
title_sort sars-cov-2 omicron ba.1/ba.2 neutralization up to 8 weeks after prep with sotrovimab or cilgavimab/tixagevimab
topic Health Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790897/
https://www.ncbi.nlm.nih.gov/pubmed/36578452
http://dx.doi.org/10.3389/ti.2022.10906
work_keys_str_mv AT stiasnykarin sarscov2omicronba1ba2neutralizationupto8weeksafterprepwithsotrovimaborcilgavimabtixagevimab
AT weseslindtnerlukas sarscov2omicronba1ba2neutralizationupto8weeksafterprepwithsotrovimaborcilgavimabtixagevimab
AT heinzelandreas sarscov2omicronba1ba2neutralizationupto8weeksafterprepwithsotrovimaborcilgavimabtixagevimab
AT campjeremyv sarscov2omicronba1ba2neutralizationupto8weeksafterprepwithsotrovimaborcilgavimabtixagevimab
AT oberbauerrainer sarscov2omicronba1ba2neutralizationupto8weeksafterprepwithsotrovimaborcilgavimabtixagevimab
AT reindlschwaighoferroman sarscov2omicronba1ba2neutralizationupto8weeksafterprepwithsotrovimaborcilgavimabtixagevimab

Ejemplares similares